446 related articles for article (PubMed ID: 22689675)
21. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B
Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320
[TBL] [Abstract][Full Text] [Related]
22. Multiple Extramedullary-Bone Related and/or Extramedullary Extraosseous Are Independent Poor Prognostic Factors in Patients With Newly Diagnosed Multiple Myeloma.
He J; Yue X; He D; Zhao Y; Yang Y; Zheng G; Zhang E; Han X; Wu W; Yang L; Chen J; Cai Z
Front Oncol; 2021; 11():668099. PubMed ID: 34307138
[TBL] [Abstract][Full Text] [Related]
23. Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
Gagelmann N; Eikema DJ; Koster L; Caillot D; Pioltelli P; Lleonart JB; Reményi P; Blaise D; Schaap N; Trneny M; Passweg J; Porras RP; Cahn JY; Musso M; Poiré X; Fenk R; Itälä-Remes M; Pavone V; Fouillard L; Maertens J; Bron D; Pouli A; Schroyens W; Schönland S; Garderet L; Yakoub-Agha I; Kröger N
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2134-2142. PubMed ID: 31288095
[TBL] [Abstract][Full Text] [Related]
24. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
[TBL] [Abstract][Full Text] [Related]
25. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.
Bladé J; Fernández de Larrea C; Rosiñol L; Cibeira MT; Jiménez R; Powles R
J Clin Oncol; 2011 Oct; 29(28):3805-12. PubMed ID: 21900099
[TBL] [Abstract][Full Text] [Related]
26. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma.
Haznedar R; Akı SZ; Akdemir OU; Ozkurt ZN; Ceneli O; Yağcı M; Sucak GT; Unlü M
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1046-53. PubMed ID: 21287167
[TBL] [Abstract][Full Text] [Related]
27. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.
Zamagni E; Patriarca F; Nanni C; Zannetti B; Englaro E; Pezzi A; Tacchetti P; Buttignol S; Perrone G; Brioli A; Pantani L; Terragna C; Carobolante F; Baccarani M; Fanin R; Fanti S; Cavo M
Blood; 2011 Dec; 118(23):5989-95. PubMed ID: 21900189
[TBL] [Abstract][Full Text] [Related]
28. Correlation Between Uptake of
Li Q; Ma J; Li H; Xu W; Cao Z; Liu S; Chen L; Gao S; Yan T; Li D; Wang X; Yue Y; Zhao Z; Wang X; Yang H; Zhao H; Yu Y; Zhang Y; Fan F; Wang Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819849067. PubMed ID: 31092140
[TBL] [Abstract][Full Text] [Related]
29. Extramedullary involvement in multiple myeloma.
Bladé J; de Larrea CF; Rosiñol L
Haematologica; 2012 Nov; 97(11):1618-9. PubMed ID: 23125242
[No Abstract] [Full Text] [Related]
30. Extramedullary Myeloma of the Uterus on 18F-FDG PET/CT: A Rare Manifestation of Multiple Myeloma.
Causa Andrieu PI; Das JP; Woo S; Ryan R; Akin O; Ulaner GA
Clin Nucl Med; 2020 Nov; 45(11):873-875. PubMed ID: 32657873
[TBL] [Abstract][Full Text] [Related]
31. The possible role of burden of therapy on the risk of myeloma extramedullary spread.
Mangiacavalli S; Pompa A; Ferretti V; Klersy C; Cocito F; Varettoni M; Cartia CS; Cazzola M; Corso A
Ann Hematol; 2017 Jan; 96(1):73-80. PubMed ID: 27766391
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of
Han S; Woo S; Kim YI; Yoon DH; Ryu JS
Eur Radiol; 2021 Jan; 31(1):152-162. PubMed ID: 32809165
[TBL] [Abstract][Full Text] [Related]
33. Extramedullary Disease in Multiple Myeloma.
Jagosky MH; Usmani SZ
Curr Hematol Malig Rep; 2020 Apr; 15(2):62-71. PubMed ID: 32198576
[TBL] [Abstract][Full Text] [Related]
34. Pretreatment
Abe Y; Narita K; Kobayashi H; Kitadate A; Miura D; Takeuchi M; O'uchi E; O'uchi T; Matsue K
Eur J Nucl Med Mol Imaging; 2019 Jun; 46(6):1325-1333. PubMed ID: 30687892
[TBL] [Abstract][Full Text] [Related]
35. Whole-body (18)F-FDG PET identifies high-risk myeloma.
Durie BG; Waxman AD; D'Agnolo A; Williams CM
J Nucl Med; 2002 Nov; 43(11):1457-63. PubMed ID: 12411548
[TBL] [Abstract][Full Text] [Related]
36. How I treat extramedullary myeloma.
Touzeau C; Moreau P
Blood; 2016 Feb; 127(8):971-6. PubMed ID: 26679866
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of [
Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
[TBL] [Abstract][Full Text] [Related]
38. Solitary plasmacytoma of bone and soft tissue.
Bolek TW; Marcus RB; Mendenhall NP
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):329-33. PubMed ID: 8892456
[TBL] [Abstract][Full Text] [Related]
39. PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.
Zamagni E; Nanni C; Mancuso K; Tacchetti P; Pezzi A; Pantani L; Zannetti B; Rambaldi I; Brioli A; Rocchi S; Terragna C; Martello M; Marzocchi G; Borsi E; Rizzello I; Fanti S; Cavo M
Clin Cancer Res; 2015 Oct; 21(19):4384-90. PubMed ID: 26078390
[TBL] [Abstract][Full Text] [Related]
40. Cytogenetics in multiple myeloma patients progressing into extramedullary disease.
Besse L; Sedlarikova L; Greslikova H; Kupska R; Almasi M; Penka M; Jelinek T; Pour L; Adam Z; Kuglik P; Krejci M; Hajek R; Sevcikova S
Eur J Haematol; 2016 Jul; 97(1):93-100. PubMed ID: 26432667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]